Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838–857 (2021).
Kim, T. K., Vandsemb, E. N., Herbst, R. S. & Chen, L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat. Rev. Drug Discov. 21, 529–540 (2022).
Wang, E. Y. et al. High-throughput identification of autoantibodies that target the human exoproteome. Cell Rep. Methods 2, 100172 (2022).
Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
Sade-Feldman, M. et al. Defining T cell states blockociated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013.e20 (2018).
Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527–541.e5 (2022).
Mazor, R. D. et al. Tumor-reactive antibodies evolve from non-binding and autoreactive precursors. Cell 185, 1208–1222.e21 (2022).
Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561–565 (2020).
Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549–555 (2020).
Petitprez, F. et al. B cells are blockociated with survival and immunotherapy response in sarcoma. Nature 577, 556–560 (2020).
Rivera, A., Chen, C. C., Ron, N., Dougherty, J. P. & Ron, Y. Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations. Int. Immunol. 13, 1583–1593 (2001).
Bruno, T. C. et al. Antigen-presenting intratumoral B cells affect CD4+ TIL phenotypes in non-small cell lung cancer patients. Cancer Immunol. Res. 5, 898–907 (2017).
Cui, C. et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses. Cell 184, 6101–6118.e13 (2021).
Kotera, Y., Fontenot, J. D., Pecher, G., Metzgar, R. S. & Finn, O. J. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 54, 2856–2860 (1994).
Disis, M. L. et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol. 15, 3363–3367 (1997).
Ludwig, R. J. et al. Mechanisms of autoantibody-induced pathology. Front. Immunol. 8, 603 (2017).
Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).
Wang, E. Y. et al. Diverse functional autoantibodies in patients with COVID-19. Nature 595, 283–288 (2021).
Britschgi, M. et al. Neuroprotective natural antibodies to blockemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer’s disease. Proc. Natl Acad. Sci. USA 106, 12145–12150 (2009).
Jaycox, J. R., Dai, Y. & Ring, A. M. Decoding the autoantibody reactome. Science 383, 705–707 (2024).
Dimitrov, J. D. & Lacroix-Desmazes, S. Noncanonical functions of antibodies. Trends Immunol. 41, 379–393 (2020).
Wang, J. et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell 176, 334–347.e12 (2019).
Yu, X. et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat. Immunol. 10, 48–57 (2009).
Jaiswal, S. et al. CD47 is up-regulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138, 271–285 (2009).
Hailemichael, Y. et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell 40, 509–523.e6 (2022).
Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554.e12 (2016).
Vitiello, G. A. & Miller, G. Targeting the interleukin-17 immune axis for cancer immunotherapy. J. Exp. Med. 217, e20190456 (2020).
Huseni, M. A. et al. CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep. Med. 4, 100878 (2023).
Salazar, V. S., Gamer, L. W. & Rosen, V. BMP signalling in skeletal development, disease and repair. Nat. Rev. Endocrinol. 12, 203–221 (2016).
Thomas, C. et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 146, 621–632 (2011).
van der Wijst, M. G. P. et al. Type I interferon autoantibodies are blockociated with systemic immune alterations in patients with COVID-19. Sci. Transl. Med. 13, eabh2624 (2021).
Hamilton, J. A. et al. Endogenous interferon-β regulates survival and development of transitional B cells. J. Immunol. 199, 2618–2623 (2017).
Antonelli, G., Scagnolari, C., Moschella, F. & Proietti, E. Twenty-five years of type I interferon-based treatment: a critical ***ysis of its therapeutic use. Cytokine Growth Factor Rev. 26, 121–131 (2015).
Benci, J. L. et al. Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade. Cell 178, 933–948.e14 (2019).
Reticker-Flynn, N. E. et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell 185, 1924–1942.e23 (2022).
Mathew, D. et al. Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients. Science 384, eadf1329 (2024).
Zak, J. et al. JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma. Science 384, eade8520 (2024).
Giles, J. R. et al. Shared and distinct biological circuits in effector, memory and exhausted CD8+ T cells revealed by temporal single-cell transcriptomics and epigenetics. Nat. Immunol. 23, 1600–1613 (2022).
Zhu, J., Petit, P.-F. & Van den Eynde, B. J. Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism. Cancer Immunol. Immunother. 68, 835–847 (2019).
Wang, E. C. Y. et al. DR3 regulates negative selection during thymocyte development. Mol. Cell. Biol. 21, 3451–3461 (2001).
Wack, A., Terczyńska-Dyla, E. & Hartmann, R. Guarding the frontiers: the biology of type III interferons. Nat. Immunol. 16, 802–809 (2015).
Tang, Z. et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive ***yses. Nucleic Acids Res. 45, W98–W102 (2017).
Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events blockociated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).
de Moel, E. C. et al. Autoantibody development under treatment with immune-checkpoint inhibitors. Cancer Immunol. Res. 7, 6–11 (2019).
Weber, J. S. et al. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): a pooled ***ysis. J. Clin. Oncol. 33, 9018–9018 (2015).
Jiang, Y. et al. Identification and characterization of a novel RF-amide peptide ligand for orphan G-protein-coupled receptor SP9155. J. Biol. Chem. 278, 27652–27657 (2003).
Cohen, J. C., Boerwinkle, E., Mosley, T. H. & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264–1272 (2006).
Furie, R. et al. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 69, 376–386 (2017).
Bradford, H. F. et al. Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsets. Cell Rep. Med. 4, 100894 (2023).
Bastard, P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol. 6, eabl4340 (2021).
Michot, J. M. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139–148 (2016).
The UniProt Consortium. UniProt: the universal protein knowledgebase. Nucleic Acids Res. 46, 2699 (2018).
Subramanian, A. et al. Gene set enrichment ***ysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
Migone, T. S. et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16, 479–492 (2002).
Qin, K. et al. Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: a prospective cohort study. PLoS Med. 20, e1004157 (2023).
Zhou, T. et al. IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 583, 609–614 (2020).
